127 related articles for article (PubMed ID: 28978265)
1. Modulation of interaction of mutant TP53 and wild type BRCA1 by alkaloids: a computational approach towards targeting protein-protein interaction as a futuristic therapeutic intervention strategy for breast cancer impediment.
Tiwari S; Awasthi M; Singh S; Pandey VP; Dwivedi UN
J Biomol Struct Dyn; 2018 Oct; 36(13):3376-3387. PubMed ID: 28978265
[TBL] [Abstract][Full Text] [Related]
2. BRCA1/TP53 tumor proteins inhibited by novel analogues of curcumin - Insight from computational modelling, dynamic simulation and experimental validation.
Aloor LJ; Skariyachan S; Raghavamenon AC; Kumar KM; Narayanappa R; Uttarkar A; Niranjan V; Cherian T
Int J Biol Macromol; 2023 Dec; 253(Pt 4):126989. PubMed ID: 37739292
[TBL] [Abstract][Full Text] [Related]
3. Modulation of interaction of BRCA1-RAD51 and BRCA1-AURKA protein complexes by natural metabolites using as possible therapeutic intervention toward cardiotoxic effects of cancer drugs: an
Tiwari S; Pandey VP; Yadav K; Dwivedi UN
J Biomol Struct Dyn; 2022; 40(23):12863-12879. PubMed ID: 34632941
[TBL] [Abstract][Full Text] [Related]
4. Screening and identification of phytochemical drug molecules against mutant BRCA1 receptor of breast cancer using computational approaches.
Singh J; Sangwan N; Chauhan A; Sarma P; Prakash A; Medhi B; Avti PK
Mol Cell Biochem; 2022 Mar; 477(3):885-896. PubMed ID: 35067782
[TBL] [Abstract][Full Text] [Related]
5. Performance of a docking/molecular dynamics protocol for virtual screening of nutlin-class inhibitors of Mdmx.
Bharatham N; Finch KE; Min J; Mayasundari A; Dyer MA; Guy RK; Bashford D
J Mol Graph Model; 2017 Jun; 74():54-60. PubMed ID: 28351017
[TBL] [Abstract][Full Text] [Related]
6. Lipoxygenase directed anti-inflammatory and anti-cancerous secondary metabolites: ADMET-based screening, molecular docking and dynamics simulation.
Singh S; Awasthi M; Pandey VP; Dwivedi UN
J Biomol Struct Dyn; 2017 Feb; 35(3):657-668. PubMed ID: 26942689
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the
Chitrala KN; Nagarkatti M; Nagarkatti P; Yeguvapalli S
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31216622
[TBL] [Abstract][Full Text] [Related]
8. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
9. Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.
Valenti F; Ganci F; Fontemaggi G; Sacconi A; Strano S; Blandino G; Di Agostino S
Oncotarget; 2015 Mar; 6(8):5547-66. PubMed ID: 25650659
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
[TBL] [Abstract][Full Text] [Related]
11. Cancer-related mutations in BRCA1-BRCT cause long-range structural changes in protein-protein binding sites: a molecular dynamics study.
Gough CA; Gojobori T; Imanishi T
Proteins; 2007 Jan; 66(1):69-86. PubMed ID: 17063491
[TBL] [Abstract][Full Text] [Related]
12. DNA topoisomerase-directed anticancerous alkaloids: ADMET-based screening, molecular docking, and dynamics simulation.
Singh S; Das T; Awasthi M; Pandey VP; Pandey B; Dwivedi UN
Biotechnol Appl Biochem; 2016; 63(1):125-37. PubMed ID: 25594242
[TBL] [Abstract][Full Text] [Related]
13. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
14. Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy.
Li J; Yang L; Gaur S; Zhang K; Wu X; Yuan YC; Li H; Hu S; Weng Y; Yen Y
Hum Mutat; 2014 May; 35(5):575-84. PubMed ID: 24677579
[TBL] [Abstract][Full Text] [Related]
15. Enhanced breast cancer progression by mutant p53 is inhibited by the circular RNA circ-Ccnb1.
Fang L; Du WW; Lyu J; Dong J; Zhang C; Yang W; He A; Kwok YSS; Ma J; Wu N; Li F; Awan FM; He C; Yang BL; Peng C; MacKay HJ; Yee AJ; Yang BB
Cell Death Differ; 2018 Dec; 25(12):2195-2208. PubMed ID: 29795334
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
17. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
[TBL] [Abstract][Full Text] [Related]
18. A structural bioinformatics approach to explore the interactions of P53 and BRCA1 gene products on ovarian and breast cancer.
Parija S; Kumar A
Int J Bioinform Res Appl; 2011; 7(1):1-14. PubMed ID: 21441093
[TBL] [Abstract][Full Text] [Related]
19. Computational screening and molecular dynamic simulation of breast cancer associated deleterious non-synonymous single nucleotide polymorphisms in TP53 gene.
Chitrala KN; Yeguvapalli S
PLoS One; 2014; 9(8):e104242. PubMed ID: 25105660
[TBL] [Abstract][Full Text] [Related]
20. In silico assessment of new progesterone receptor inhibitors using molecular dynamics: a new insight into breast cancer treatment.
Zarezade V; Abolghasemi M; Rahim F; Veisi A; Behbahani M
J Mol Model; 2018 Nov; 24(12):337. PubMed ID: 30415281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
